Vir Biotechnology — Third Quarter 2026 Earnings Summary

Vir Biotechnology reported a net loss of $96.3 million for the third quarter of 2026, driven by $80.0 million in research and development expenses. The company's cash, cash equivalents, and investments totaled approximately $901.3 million as of September 30, 2026. Topline data from the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta is expected in the fourth quarter of 2026, while the oncology candidate VIR-5500 received FDA Fast Track designation and achieved proof of concept. Additionally, Vir entered a collaboration with Gilead to develop three novel T-cell engager candidates, receiving a $65 million upfront payment and a $25 million equity investment.